Wealth Effects LLC Purchases Shares of 6,417 CVS Health Corporation $CVS

Wealth Effects LLC acquired a new position in shares of CVS Health Corporation (NYSE:CVS) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 6,417 shares of the pharmacy operator’s stock, valued at approximately $664,000.

Several other institutional investors have also recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd increased its position in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the fourth quarter valued at $26,000. Sankala Group LLC purchased a new stake in CVS Health during the 4th quarter worth about $28,000. Global Trust Asset Management LLC increased its position in CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new position in CVS Health in the 4th quarter valued at about $28,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CVS Health

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 3,372,000 shares of company stock worth $317,473,598 over the last ninety days. 0.85% of the stock is currently owned by insiders.

CVS Health Trading Down 0.1%

Shares of CVS stock opened at $97.09 on Monday. The firm’s 50-day simple moving average is $102.52 and its 200-day simple moving average is $88.26. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1-year low of $67.42 and a 1-year high of $110.68. The firm has a market cap of $124.18 billion, a P/E ratio of 25.69, a PEG ratio of 0.93 and a beta of 0.61.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities analysts forecast that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Weiss Ratings raised shares of CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of CVS Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. HSBC restated a “hold” rating and set a $103.00 target price on shares of CVS Health in a research report on Monday, July 6th. Robert W. Baird set a $107.00 price target on CVS Health in a report on Thursday, August 6th. Finally, Piper Sandler restated an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. Twenty-two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.75.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.